Trials / Completed
CompletedNCT01175148
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Phase II Study Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft-versus-host Disease in Patients Undergoing Matched Sibling Hematopoietic Stem Cell Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- West Virginia University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Atorvastatin for prevention of acute GVHD
Detailed description
This is a phase II study of atorvastatin for the prophylaxis of acute GVHD in patients undergoing matched-sibling allogeneic HSCT. This study will explore a two-pronged acute GVHD prophylaxis strategy, consisting of pre-treating consenting sibling donors with atorvastatin before stem cell collection, followed by the addition of atorvastatin to methotrexate/tacrolimus-based GVHD prophylaxis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin calcium (Lipitor) | 40 mg PO daily |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2010-08-04
- Last updated
- 2017-06-07
- Results posted
- 2017-06-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01175148. Inclusion in this directory is not an endorsement.